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Abstract
Background: Specific immunological unresponsiveness to alloantigens can be induced in vivo by treating mice with a
donor alloantigen in combination with a non-depleting anti-CD4 antibody. This tolerance induction protocol enriches for
alloantigen reactive regulatory T cells (Treg). We previously demonstrated that alpha-1,2-mannosidase, an enzyme involved
in the synthesis and processing of N-linked glycoproteins, is highly expressed in tolerant mice, in both graft infiltrating
leukocytes and peripheral blood lymphocytes.
Principal Findings: In this study we have identified that alpha-1,2-mannosidase expression increases in CD25
+CD4
+ Treg
when they encounter alloantigen in vivo. When alpha-1,2-mannosidase enzyme activity was blocked, Treg retained their
capacity to suppress T cell proliferation in vitro but were unable to bind to physiologically relevant ligands in vitro. Further in
vivo analysis demonstrated that blocking alpha-1,2-mannosidase in Treg resulted in the migration of significantly lower
numbers to the peripheral lymph nodes in skin grafted mice following adoptive transfer, where they were less able to
inhibit the proliferation of naı ¨ve T cells responding to donor alloantigen and hence unable prevent allograft rejection in
vivo.
Significance: Taken together, our results suggest that activation of alloantigen reactive Treg results in increased alpha-1,2-
mannosidase expression and altered N-glycosylation of cell surface proteins. In our experimental system, altered N-
glycosylation is not essential for intrinsic Treg suppressive capacity, but is essential in vivo as it facilitates Treg migration to
sites where they can regulate immune priming. Migration of Treg is central to their role in regulating in vivo immune
responses and may require specific changes in N-glycosylation upon antigen encounter.
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Introduction
Glycosylation involves the addition and removal of carbohy-
drate moieties to newly synthesized proteins orchestrated by a
sequence of enzymes in the Golgi and endoplasmic reticulum [1].
It is a highly regulated process and specific oligosaccharides can
alter both protein stability and function. Asparagine (N)-linked
glycans are one kind of carbohydrate moiety found on cell surface
glycoproteins; divided into high mannose-, hybrid- and complex-
type according to the sugar component and the structure of sugar
chains linking to the common oligosaccharide core (Man3-
GlcNAc2) [2]. There is considerable evidence that N-glycans play
a key role in immune regulation [1].
N-glycosylation is tightly controlled during both the differentia-
tionand activation ofT lymphocytesand determinesthe ability of T
cells to respond to extracellular stimuli and mediate cell-cell
interactions [1,3,4,5,6,7]. Ablation of the glycosyltransferase Mgat5
leads to increased TCR signaling and autoimmune disease in vivo,
due to the loss of N-glycans that mediate the interaction of TCR
molecules with galectins and hence restriction of TCR clustering
[3]. Removal of N-glycosylation sites in the TCR constant domain
canalsoincrease the avidityofthe TCR[8],whichisbeingexplored
as a strategy to target cancer cells. Activation of mouse CD4
+ and
CD8
+ T cells leads to dramaticremodelingof terminal glycosylation
patterns of N-glycans which may alter the recognition of activated
and resting T cells by other cell types expressing glycan-binding
proteins that recognize terminal sequences of N-glycans [9].
Alpha-1,2-mannosidase is an enzyme involved in the synthesis
and maturation of N-glycoproteins, where it successively removes
mannose residues from Man9GlcNAc2 to generate Man5GlcNAc2
[10]. Our laboratory identified alpha-1,2-mannosidase as a marker
that is highly expressed during induction and maintenance of
operational tolerance to alloantigens in vivo resulting in allograft
acceptance of both kidney and heart grafts, in two species, rat and
mouse [11]. Alpha-1,2-mannosidase (Entrez GeneID: 17155)
mRNA shows a strong positive correlation with graft function and
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8894decreases in both peripheral blood leukocytes and graft infiltrating
leukocytes prior to rejection, suggesting that it may be useful marker
for monitoring allograft function in clinical transplantation [11].
Achieving immunological tolerance to donor alloantigens without
theneedforlong-termadministrationofimmunosuppressivedrugsis
a major goal in transplantation.Regulatory T cells (Treg) comprise a
subset of T lymphocytes that can suppress immune responses,
control immune responsiveness to donor alloantigens, and have the
potential to play a role in both inducing and maintaining transplant
tolerance in vivo [12]. In animals expressing alpha-1,2-mannosidase,
we have shown that immunological unresponsiveness to alloantigen
is dependent on Treg [13] and that alpha-1,2-mannosidase mRNA
is upregulated in Treg when they re-encounter alloantigen in vivo.
Here we have investigated the hypothesis that alpha-1,2-mannosi-
dase function and hence N-glycosylation, is required for Treg
function and migration in vivo. We show that alpha-1,2-mannosidase
function is not required for the suppressive capacity of Treg in vitro,
bu tin fl ue nc e sTr e gad h er e nc einvitroand migration invivo.Defectsin
migration of Treg treated with kifunensine (KIF) that specifically
inhibits the catalytic activity of alpha-1,2-mannosidase [14,15],
results intheir impaired abilityto prevent effectorT cell priming and
hence rejection of allogeneic skin grafts. These data suggest that
upon alloantigen encounter, increased alpha-1,2-mannosidase and
hence N-glycosylation are important for Treg function as they
facilitate their transit in vivo to sites where they can suppress T cell
activation leading to tissue pathology, as demonstrated in this model
by rejection of donor allografts.
Results
Alpha-1,2-Mannosidase Expression Increases in Activated
Alloantigen Reactive Treg
T cell-mediated processes including activation and homing are
accompanied by changes in cell surface N-glycosylation which
result in an N-glycan signature [9]. Alpha-1,2-mannosidase is a
key enzyme involved in directing this process of N-glycosylation.
We have shown previously that alpha-1,2-mannosidase is
upregulated in graft infiltrating leukocytes from long-term
surviving heart grafts following pre-treatment of mice with donor
alloantigen (DST) under the cover of anti-CD4 therapy (177) [11].
CD25
+CD4
+ Treg with the capacity to prevent skin allograft
rejection are generated following this 177/DST protocol
[13,16,17]. Therefore, we wanted to determine whether alloan-
tigen-reactive Treg upregulate alpha-1,2-mannosidase upon
antigen encounter. Following pre-treatment of mice with the
177/DST tolerance induction protocol, either one or three days
before harvest mice received an alloantigen DST reboost to
reactivate alloantigen reactive T cells in vivo, as shown in Figure 1a.
Although only a small fraction of cells are believed to be donor-
specific, we have previously detected significant differences in
mRNA expression by Treg following re-stimulation with donor
alloantigen using this protocol [18]. Treg or CD25
2CD4
+ cells
were purified from the spleens of these mice by FACS sorting and
alpha-1,2-mannosidase mRNA was quantified by real-time PCR,
normalized to CD3. Figure 1b shows approximately a four-fold
increase in alpha-1,2-mannosidase mRNA expression in
CD25
+CD4
+ cells 24h after DST. This increase is transient as
expression returns to basal levels 3 days after alloantigen exposure,
and is not observed in CD25
2CD4
+ cells.
Expression of N-Glycans Increases on the Cell Surface of
Activated Treg
Activation of mouse splenic CD4
+ and CD8
+ T cells leads to
dramatic remodeling of N-glycans [9]. Indeed T cell activation
results in increased N-glycosylation on cell surface proteins [3]. In
order to assay whether the increased alpha-1,2-mannosidase
mRNA associated with activation of Treg is accompanied with
changes in the level of cell surface protein N-glycans, we
stimulated CD25
+CD4
+ Treg in vitro and quantified N-glycosyl-
ation with Phaseolus vulgaris leucoagglutinin (PHA-L) which binds
specifically to tri- or tetra-antennary complex type N-glycans with
b1-6 linked branching [19]. Although the 177/DST tolerance
induction protocol enriches for alloantigen-specific Treg, alloan-
tigen reactive Treg cannot be distinguished from Treg with other
specificities present in the pretreated mice [20]. CD25
+CD4
+ T
cells purified from 177/DST pretreated mice were therefore
stimulated polyclonally in vitro with CD3/CD28 beads to ensure
uniform activation. Figure 2a shows that polyclonal activation of
Treg is accompanied with an increase in N-glycan expression on
the cell surface (resting –v- activated Treg: MFI 89 –v- 312).
Interestingly, naı ¨ve Treg express more cell surface N-glycans than
CD25
2CD4
+ cells (Fig 2b Treg –v- CD25
2CD4
+: MFI 99 –v- 29).
These data were verified using FACS sorted CD4
+GFP
+ Treg
from Foxp3 knockin mice [21] (data not shown).
In order to assess whether blocking alpha-1,2-mannosidase
activity with KIF corresponds with decreased Treg cell surface N-
glycosylation, cells were incubated with KIF for 30 min and after
washing were activated for 24 hours with CD3/CD28 beads. Treg
incubated with KIF (Treg
KIF) had decreased surface N-glycan
Figure 1. Alpha-1,2-mannosidase expression is increased in
CD25
+CD4
+ cells after alloantigen re-challenge in vivo. a) CBA
were pre-treated with an anti-CD4 mAb at days -28 and -27 (200 mg YTS
177). At day -27, mice also received an allogeneic blood transfusion
(250 ml B10, DST). At days -3 or -1, mice received a DST reboost.
CD25
+CD4
+ and CD25
2CD4
+ cells were purified from the spleen of
these animals at day 0. RNA was extracted from these cells and cDNA
was synthesized. (b) Alpha-1,2-mannosidase expression was assessed by
Real Time RT-PCR. CD3 expression was measured to normalise the
cDNA concentration in each sample. Error bars represent the standard
deviation. The data presented are representative of 4 separate
experiments.
doi:10.1371/journal.pone.0008894.g001
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(Fig 2c Treg
KIF –v-Treg: MFI 14 –v- 312). The decreased N-
glycosylation was less pronounced in KIF-treated cells that were
cultured for 24 h without anti-CD3/CD28 stimulation (Fig 2d
Treg
KIF –v-Treg: MFI 66 –v-89) indicating that there is a faster
turnover of N-glycosylated cell surface proteins in activated Treg.
N-Glycosylation Is Not Required for Treg Suppression In
Vitro
It is well established that N-glycosylation of T cells alters their
function [3,22,23,24,25]. Therefore we wanted to establish
whether alpha-1,2-mannosidase function and hence N-linked
glycosylation of proteins synthesized by Treg are required for
their ability to suppress effector T cell responses. Due to the
finding that cells pre-incubated with KIF had a more pronounced
decrease in N-glycans on their cell surface after stimulation (fig 2c
and 2d), Treg or Treg
KIF were cultured for 24 hours with IL-2
plus CD3/CD28 beads to allow the N-glycan profile of cells to
change. Cells were then washed and co-cultured at decreasing
ratios in an in vitro MLR with CFSE-labeled CBK CD25
2CD4
+
responder T cells and either CD3/CD28 beads or irradiated B10
APC stimulators. CBK cells are genetically identical to CBA, with
the exception that they express the MHC I molecule K
b transgene
which allows them to be distinguished from K
b2 Treg. After
6 days in culture the number of responder T cells that had gone
through at least one cell division was quantified. Figure 3 shows
that the ability of Treg
KIF cells to regulate CD25
2CD4
+ cells was
not impaired, when cells were stimulated with either irradiated
B10 APC (Fig 3a) or CD3/CD28 expander beads (Fig 3b).
Moreover, the ability of Treg
KIF to suppress to an alloantigen
response was significantly better than Treg at ratios of 1:1 (Treg
9672 +/2 1512–v- Treg
KIF 2566 +/2 1259 divided CD25
2CD4
+
cells; p,0.05) up to 1:8 (Treg 66381 +/2 10220 –v- Treg
KIF
19210 +/2 3885 divided CD25
2CD4
+ cells; p,0.05). Hence,
inhibiting N-glycosylation does not decrease the ability of Treg to
regulate in vitro, and may even increase their suppressive capacity.
Alpha-1,2-Mannosidase Inhibition Abrogates Treg
Adherence In Vitro
N-glycosylation of many cell-surface molecules orchestrates
their ability to bind to their respective ligands. Indeed inhibition of
alpha-1,2-mannosidase with an alternative inhibitor deoxymanno-
jirimycin results in decreased adherence of human lymphocytes to
endothelial cells [26] suggesting that alpha-1,2-mannosidase and
hence correct N-glycosylation regulates adherence.
Our original identification of alpha-1,2-mannosidase levels
associating with tolerance was identified in animals that had
received a heart allograft [11]. In these animals Treg are likely to
exit the peripheral blood to the peripheral lymphoid tissues and
the graft where they can inhibit activation and effector function of
immune cells with the potential to elicit graft destruction, in a
process which requires Treg cell adherence to high endothelial
venules (HEVs) or activated graft vessel endothelial cells. Others
have identified the adherence molecules CD62L, VLA-4, and
Figure 2. Surface N-glycosylation levels increase in activated CD25
+CD4
+ T cells. Total CBA splenocytes or purified cells in culture were
stained with PHA-L and surface N-glycan levels were assayed by FACS for (a) CD25
+CD4
+ cells cultured for 24 h with or without anti-CD3/28 beads in
the presence of rhIL-2 (b) Naı ¨ve CBA splenocytes gated on CD25
2CD4
+ and CD25
+CD4
+ T cells (c) CD25
+CD4
+ cells incubated with either PBS
(CD25
+CD4
+) or KIF (CD25
+CD4
+KIF) for 30 min followed by culture for 24 h with rhIL-2 + anti-CD3/CD28 beads (d) CD25
+CD4
+ cells incubated with
either PBS (CD25
+CD4
+) or KIF (CD25
+CD4
+KIF) for 30 min followed by culture for 24 h with rhIL-2. The data presented are representative of 3 separate
experiments.
doi:10.1371/journal.pone.0008894.g002
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axilliary LNs [27]. Therefore we assayed the ability of Treg or
Treg
KIF to bind to ligands of CD62L, VLA-4, and LFA-1 in an in
vitro adherence assay (Fig 4a). Treg were incubated on tissue
culture plates coated with either BSA (negative control),
fibronectin, ICAM-1 or MADCAM (binding by VLA-4, LFA-1
or CD62L respectively). Treg and Treg
KIF adhered to BSA at
background levels and there was a trend towards less Treg
KIF
binding to fibronectin although this was not statistically significant.
A small but significant decrease was detected in the binding of
Treg
KIF to ICAM-1 (Treg 41%63.7, Treg
KIF 33%65.5; p,0.05).
The decreased ability of Treg
KIF to bind to MADCAM was more
pronounced (Treg 15.7%64, Treg
KIF 3.7%60.6; p,0.05). These
data show that Treg
KIF bind less efficiently to certain physiolog-
ically relevant ligands in vitro.
In vivo CD62L recognizes specific ligands on the HEVs of
axillary lymph nodes and is considered the homing receptor for
secondary lymphoid tissues [28]. CD62L is intensely glycosylated
and its ability to bind to ligands in vitro depends on its glycosylation
[29]. In order to confirm whether correct N-glycosylation of
CD62L may facilitate Treg binding to HEV, we assessed the
ability of Treg and Treg
KIF to bind axilliary LN sections in a
modified Stamper Woodruff assay [30]. Approximately 10 Treg
bound per HEV in vitro (Fig 4b). Virtually no Treg
KIF bound to
HEV which was equivalent to incubating Treg with a CD62L-
blocking antibody (Mel-14) (fig 4b). Interestingly, unlike Treg, high
non-specific binding of Treg
KIF to the tissue sections at sites other
than the HEV was observed, which was not inhibited by blocking
CD62L (data not shown), suggesting that while inhibiting alpha-
Figure 3. Treg
KIF retain their suppressive function in an in vitro
MLR. Treg were purified from CBA mice and incubated for 30 mins
with either PBS or KIF. Treg were cultured with CD3/CD28 beads with
rhIL-2 for 24 hours and cultured at decreasing ratios with 1610
5 CFSE-
labelled CD25
2CD4
+ effector K
b+ T cells along with (a) 3610
5 irradiated
B10.B10S.F1 splenocytes or (b) 1610
5 CD3/CD28 beads. After 6 days the
cultures were harvested and numbers of divided CD25
2CD4
+ effector
K
b+ T cells were calculated by FACS. Error bars represent the standard
deviation. Experiments were carried out in triplicate and data are
representative of 3 separate experiments. * p,0.05.
doi:10.1371/journal.pone.0008894.g003 Figure 4. Adherence of Treg to various substrates after pre-
incubation with KIF. Treg were purified from CBA mice and
incubated for 30 mins with either PBS or KIF. Cells were cultured with
CD3/CD28 beads with rhIL-2 for 24 hours. (a) 2610
4 cells were plated
on Maxisorp plates coated with various substrates. After 45 min non-
adherent cells were removed by washing and the percentage of
adherent cells was quantified using CellTitre Glo (Promega). The
percentage adherent cells after pre-incubation of Treg with PBS (Treg)
or KIF (Treg
KIF) is shown. (b) A modified Stamper-Woodruff protocol was
performed. 10
5 Treg were added to CBA ALN tissue sections and
rotated over the sections for 45 min. Unbound cells were removed by
washing in PBS. Treg bound to HEV were fixed. To block L-selectin
binding, cells were pre-treated with Mel-14 antibody. The number of
CFSE-labeled cells bound to HEV was counted blind. (n.d; not detected).
Error bars represent the standard deviation. Experiments were carried
out in triplicate and data are representative of 4 separate experiments.
*p,0.05.
doi:10.1371/journal.pone.0008894.g004
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ligands, the adherence of Treg
KIF to other ligands increases.
Homing of Treg
KIF Is Disrupted In Vivo Which Allows
Effector T Cell Priming in the dALN in Mice Receiving an
Allogeneic Skin Transplant
We have previously shown that T- and B-cell deficient CBA
Rag1
2/2 mice reconstituted with BM3 T cells can reject donor skin
allografts [31]. In these animals priming of BM3 T cells occurs in
the draining axillary lymph nodes and can be detected by the
proliferation of CFSE labeled BM3 cells at day 15 post-transplant
[32]. Kinetic analysis of animals reconstituted with BM3 T cells
together with Treg from tolerant mice, has shown that Treg are
found in the draining lymph node at day 10 post-transplant where
they prevent BM3 T cell priming [33]. Next, we used this
established model to determine whether in vitro differences in
Treg
KIF adhesion translate to in vivo differences in homing.
Treg or Treg
KIF generated following the 177/DST protocol were
co-injected with 10
5 CFSE labeled effector BM3 T cells into CBA-
RAG
2/2 mice. These mice received a B10 skin transplant one day
later. 10 days post-transplant there were no significant differences in
either the number or percentage of Treg and Treg
KIF in the
mesenteric lymph nodes (MLN) and spleen (Fig 5a and 5b).
However, there was a significant reduction in the number and
percentageofTreg
KIFinboththedrainingaxillaryperipherallymph
nodes (dALN) (Treg
KIF 132622, Treg 102716193, p,0.01;
Treg
KIF 1.97%61.32, Treg 18.47%63.06, p,0.05) and contralat-
Figure 5. Ability of Kifunensine treated CD25+CD4+ cells to migrate in vivo. (a + b) CBA were pre-treated with an anti-CD4 mAb i.v. at days -
28 and -27. At day -27, mice also received specific donor blood transfusion (DST). CD25
+CD4
+ Treg were purified from the spleen of these animals at
day 0, and incubated for 30 min with either KIF or PBS. 5610
5 Treg were adoptively transferred into CBA-RAG
2/2 animals along with 10
5 CFSE labeled
BM3 T cells. One day later mice received a B10 skin graft and lymphoid organs were harvested at day 10. Treg cell (a) numbers on a log scale and (b)
percentage of total cells were analyzed by FACS. Data from n=4 animals per group. Data is representative of 3 repeats. (5c) 10
5 CFSE labeled BM3 T
cells were adoptively transferred into CBA-RAG-/- animals. One day later mice received a B10 skin graft and axillary LNs were harvested at day 10. (5d)
10
5 CD25
2CD4
+ T cells were adoptively transferred into CBA-RAG-/- animals. One day later mice received a B10 skin graft and peripheral lymphoid
organs were harvested at day 10. The number of T cells was quantified by FACS. Data from n=5 animals per group. Data are representative of 2
independent experiments. * p,0.01. Error bars represent the standard deviation.
doi:10.1371/journal.pone.0008894.g005
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KIF 155621, Treg
93856164, p,0.01; Treg
KIF 1.33%60.6, Treg 17.14%60.56,
p,0.01). The ability of BM3T cells and CD25
2CD4
+ cells to home
to the axilliary peripheral LN was not inhibited at this timepoint
(Fig 5c and 5d), although there were significantly less CD25
2CD4
+
cells in the ALN at day 5, following treatment with KIF (data not
shown). Decreased Treg
KIF number in the dALN coincided with
impaired ability of these cells to inhibit BM3 T cell priming
(Figure 6). These data suggest that Treg
KIF are unable to migrate
efficiently to the dALN, and as a result they cannot prevent BM3 T
cell priming following an allogeneic skin graft.
Treg
KIF Do Not Prevent Skin Graft Rejection Mediated by
Effector T Cells In Vivo
When CBA Rag1
2/2 are reconstituted with BM3 T cells
together with Treg from tolerant mice, prevention of BM3 T cell
priming by Treg results in survival of a B10 skin graft in most
animals [31]. In order to evaluate whether the inability of Treg
KIF
to block BM3 priming results in their defective ability to protect
allogeneic skin grafts from rejection, BM3 T cells were adoptively
transferredinto CBA-RAG
2/2 recipients alone oralong with either
pre-treated Treg or Treg
KIF. One day later these animals received a
B10 skin graft and survival was monitored over 100 days. BM3 T
cells mediated skin graft rejection with median survival time (MST)
of 25 days. Adoptive transfer of Treg at a 3:1 ratio prevented
rejection in 6 out of 8 animals with skin grafts maintained for .100
days (Figure 7a). However animals adoptively transferred with BM3
T cells + Treg
KIF at the same ratio rejected with a MST of 30 days
with only 1 out of 8 animals accepting their graft long-term.
To determine whether pre-treated Treg
KIF were also unable to
prevent rejection mediated by a heterogeneous population of
effector T cells, 1610
5 CD25
2CD4
+ T cells were adoptively
transferred into CBA-RAG
2/2 recipients alone or together with
Treg or Treg
KIF at a ratio of 1:1. CD25
2CD4
+ effector T cells
alone mediated rapid skin graft rejection (MST 19d). In agreement
with previously published data [13], co-transfer of CD25
+CD4
+ T
cells from mice pre-treated with 177/DST results in long term
survival of these grafts in CBA-RAG
-/- mice (MST .100d,
n=14), Figure 7b. In contrast, co-transfer of 1610
5 Treg
KIF
resulted in long term survival in only 3 out of 15 mice, and the
kinetics of rejection were similar to mice receiving effectors only
(MST 19d). These data suggest that in most animals Treg
KIF
cannot prevent B10 skin graft rejection by BM3 T cells or
CD25
2CD4
+ cells. Incubation of BM3 T cells or CD25
2CD4
+
cells with KIF before adoptive transfer did not alter their kinetics
of rejection (data not shown).
Discussion
We have previously shown that the induction of immunological
unresponsiveness to alloantigens in vivo correlates with an increased
expression of alpha-1,2-mannosidase in both graft infiltrating
leukocytes and peripheral blood mononuclear cells in various
animal models of tolerance, whereas decreased levels of alpha-1,2-
mannosidase serve as an indicator of rejection [11]. These
tolerance induction protocols generate alloantigen reactive Treg
[13,16,17] and we have shown here that when Treg encounter
alloantigen a transient increase in alpha-1,2-mannosidase is
observed. This suggests that alloantigen encounter results in
changes in N-glycosylation of secreted and/or cell surface proteins
by Treg, which was confirmed by N-glycan analysis of polyclonally
stimulated Treg.
Interestingly polyclonal activation in vitro of mouse CD4
+
splenocytes, which predominantly comprise CD25
2 cells, results
in decreased levels of alpha-1,2-mannosidase mRNA [11],
suggesting that both the T cell subset and the nature of T cell
activation may influence alpha-1,2-mannosidase expression.
Correct N-glycosylation could be blocked in Treg by inhibiting
alpha-1,2-mannosidase activity with KIF, which gives rise to
exclusively to high mannose structures [14], and we could detect a
decrease in N-glycosylation of cell surface proteins, particularly in
cells stimulated in vitro with CD3/CD28.
We and others have previously shown that inhibiting alpha-1,2-
mannosidase results in altered T cell behavior [11,24]. Despite
decreased cell surface N-glycans, Treg
KIF maintained their ability
to suppress effector cell proliferation in response to either
polyclonal CD3/CD28 or alloantigen stimuli in vitro. Emerging
data have identified several secreted Treg proteins that mediate
their suppressor function. These include galectins which are
proteins that can selectively kill effector T cells [34]. Galectins are
not glycosylated [35] and therefore their production and function
may not be affected by blocking alpha-1,2-mannosidase. We have
established that IFN-c production by Treg is important for their
regulatory function in vivo [18]. Deficiency in Mgat5 which is an
enzyme downstream of alpha-1,2-mannosidase in the N-glycan
Figure 6. Ability of Treg
KIF cells to inhibit BM3 T cell priming is
impaired. CBA were pre-treated with an anti-CD4 mAb i.v. at days -28
and -27. At day -27, mice also received specific donor blood transfusion
(DST). Treg from these animals were purified at day 0, and incubated for
30 minutes with either PBS or KIF. 5610
5 Treg or Treg
KIF were
adoptively transferred into CBA-RAG
2/2 animals along with 10
5 CFSE
labelled BM3 T cells. One day later (day 0) mice received a B10 skin graft.
Lymphoid organs were harvested at day 15. BM3 T cell numbers were
analyzed by FACS (cells were gated on Ti98, TCRb and CD8). n=4
animals per group. Error bars represent the standard deviation. Data are
representative of 3 experiments.
doi:10.1371/journal.pone.0008894.g006
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CD4
+ T cells when stimulated with plate-bound anti-CD3 and
anti-CD28 antibodies [25] suggesting that inhibiting N-glycosyl-
ation might not inhibit cytokine production and could actually
enhance it, which may explain the enhanced suppressor function
of Treg
KIF in vitro. The N-glycosylation of IFN-c has been well
characterized, and in the absence of correct N-glycosylation IFN-c
may have an altered binding capacity [24] although the impact of
this is unclear.
Glycosylation of cell surface proteins is integral to the ability of
cells to interact with other cells and ligands. Treg
KIF maintained
their ability to bind to fibronectin which is mediated by VLA-4
and VLA-5 [36] suggesting that alpha-1,2-mannosidase processing
of these molecules is not essential for binding. The ability of
Treg
KIF to bind to ICAM-1 was reduced suggesting that correct
N-glycosylation of LFA-1 may facilitate Treg binding to ICAM-1.
Interestingly, blocking MAN2C1, which is another enzyme in the
N-glycosylation pathway downstream of alpha-1,2-mannosidase,
results in increased binding of Jurkat human T cells to ICAM-1
[37]. Therefore the ability of Treg proteins to bind to ligands may
depend on their terminal oligosaccharides. Together these data
suggest that the effect of blocking N-glycosylation is both stage-
and cell type-dependent and the process involves complexity
which may be explained by differences in surface adherence
molecule expression between cell types. The reduced ability of
Treg
KIF to bind MADCAM in vitro was most pronounced.
Lymphocytes interact with MADCAM via CD62L and a4b7
(CD103) [38,39], which are both expressed on Treg [40]. Whilst
very little is known about N-glycosylation of a4b7, CD62L has
been shown to be intensely N-glycosylated [29]. Modification of
CD62L N-glycosylation in vitro results in altered CD62L binding to
ligands [29]. In vivo CD62L recognizes specific ligands on the
HEVs of ALN and is considered the homing receptor for
secondary lymphoid tissues [28]. Binding of CD62L to HEVs
facilitates T lymphocyte rolling which precedes adherence and
extravasation of cells into the ALN. The impaired binding to HEV
by Treg
KIF was similar to Treg that were blocked with an anti-
CD62L blocking antibody, suggesting that Treg
KIF may not be
able to bind to HEV due to changes in N-glycosylation of CD62L.
Interestingly Treg
KIF bound with high frequency to non-HEV
ALN cells. Others have shown that inhibiting alpha-1,2-manno-
sidase function increases CD44 binding to hyaluronan (HA)[41].
Therefore differences in N-glycosylation may alter the range of
ligands that Treg bind to, which facilitates trafficking of activated
Treg.
Blocking CD62L in vivo dramatically decreases migration of
mouse T cells to ALN [42]. Blocking alpha-1,2-mannosidase also
impaired migration to ALN in CBA Rag1
–/– mice reconstituted
with Treg
KIF, suggesting that alpha-1,2-mannosidase and hence
correct N-glycosylation of Treg is required for them to bind ALN
HEV and exit the peripheral blood at these sites. Interestingly, the
ability of Treg
KIF to home to the MLN and spleen was unaffected.
CD62L on T cells binds to receptors such as MADCAM,
GLYCAM and CD34 that express sialyl Lewis
a and sialyl Lewis
x
epitopes. These epitopes are constitutively expressed on the HEV
in ALN [43]. Data from CD62L-deficient mice has shown that
while Treg numbers in the ALN are significantly lower, numbers
in the MLN and spleen are similar to wild-type [44], which
suggests that other adhesion proteins may mediate homing to these
organs and may explain the differences we observe in vivo.
Figure 7. In vivo abrogation of regulation by inhibiting the function of alpha-1,2-mannosidase. The ability of Treg
KIF to prevent effector T
cell mediated allograft rejection was assayed in an adoptive transfer model. (a) CBA RAG
-/- mice were reconstituted with either (a) 10
5 BM3 T cells
purified from BM3-RAG
-/- animals or together with either 3610
5 Treg or Treg
KIF from pre-treated mice, or (b) 10
5 CD25
-CD4
+ syngeneic T cells from
naı ¨ve animals or together with either 10
5 Treg or Treg
KIF from pre-treated mice. The next day mice received an allogeneic skin graft from B10 mice.
Skin graft survival was monitored over 100 days.
doi:10.1371/journal.pone.0008894.g007
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attachment of lymphocytes to the HEV whereas treatment of
Peyer’s patches do not [45]. This indicates that distinct
mechanisms control endothelial cell attachment at different sites
and may explain the distinct requirement of correct N-glycosyl-
ation of Treg for homing to the ALN but the not MLN.
Chemokine receptors that are expressed on Treg are also essential
for homing to lymphoid organs [46,47]. Blocking chemokine
receptors with Pertussis toxin injection results in reduced Treg
numbers in the spleen [48]. Because we have observed normal
homing of Treg
KIF to the spleen and MLN we have not
investigated chemotaxis in our study, but we cannot rule out that
this may contribute to the homing impairment of Treg
KIF.
CD4
+ and CD8
+ T cells are similarly dependent on CD62L
expression for migration into lymphoid tissues [49]. However, in
contrast to Treg, following KIF treatment, at day 10 normal
numbers of BM3 T cells and CD25
2CD4
+ T cells were detected
in the ALN of reconstituted CBA Rag1
2/2, suggesting that the
requirement for N-glycosylation for homing may differ in these
cells. This is supported by the finding that effector CD8
+ T cells
can home to reactive ALN in the absence of CD62L [50].
Emerging data suggests that homing of Treg is essential for their
function [51] [52]. We have demonstrated here that alpha-1,2-
mannosidase facilitates the trafficking of Treg to the ALN where
they can prevent BM3 CD8
+ T cell priming and hence skin graft
rejection. Alpha-1,2-mannosidase may also be essential for homing
of alloantigen reactive Treg to transplanted cardiac allografts in
tolerant animals as the CD62L ligand, sialyl Lewis, is induced on
the endothelium of heart allografts that are undergoing rejection
[43]. This would explain the elevated alpha-1,2-mannosidase
detected in graft infiltrating leukocytes from tolerant animals [11].
However we have not determined the contribution of Treg to the
alpha-1,2-mannosidase signal detected in this population of
leukocytes.
During lymphoid reconstitution, homeostatic proliferation
occurs [53]. In our adoptive transfer system, Treg and Treg
KIF
undergo homeostatic proliferation and activation after reconstitu-
tion of CBA Rag1
–/– animals. In this system, inhibition of alpha-
1,2-mannosidase by KIF is transient, as by 15 days post-transplant
normal numbers of Treg
KIF are present in the ALN and they have
the correct N-glycan signature (data not shown). Interestingly
CD25
2CD4
+ T cells pretreated with KIF have reduced numbers
in the ALN at day 5 but this has reached control numbers by day
10. Given the finding that 1 out of eight, and 3 out of 15 animals
reconstituted with Treg
KIF together with BM3 T cells or
CD25
2CD4
+ cells respectively accept their grafts long-term, the
fine balance between Treg and effector T cells in the dALN during
the early immune response to the allogeneic skin graft may tip the
balance from tolerance to rejection.
Treg are not the only immune cells to express alpha-1,2-
mannosidase. Maturation of tolerogenic immature dendritic cells
is accompanied by a more than 13 fold reduction in alpha-1,2-
mannosidase mRNA, suggesting that the N-glycosylation of DCs
coincides with their ability to stimulate an effector or tolerance
response [54]. CD8
+ T cells also express alpha-1,2-mannosidase
mRNA to a similar level as CD4
+ T cells [11]. Therefore alpha-
1,2-mannosidase function may play an important role in many cell
types for controlling the immune response to allografts and may
provide a useful biomarker of tolerance. Indeed measurement of
the alpha-1,2-mannosidase mRNA levels as a ratio with FOXP3 in
peripheral blood leukocytes of human renal transplant recipients
on various immunosuppressive regimes can distinguish drug-free
tolerant patients from chronically rejecting patients (Hernandez-
Fuentes et al, submitted).
Our findings may also have implications for the clinical
immunosuppressive regimes currently employed. Mycophenolate
Mofetil (MMF) is an anti-proliferative drug currently administered
in some centers after transplantation. MMF treatment leads to a
decrease in both the expression and glycosylation of some
adhesion molecules by depleting guanosine nucleotides [55]. Rats
that have received MMF have less upregulation of adhesion
molecules in allogeneic kidney grafts which results in less
lymphocyte binding [56]. Additionally, treatment of human
CD4
+ and CD8
+ T cells with MMF results in decreased adhesion
and transendothelial cell migration [57]. The specific effects on
Treg are currently unclear.
In summary, we have shown here for the first time that the N-
glycan profile of Treg changes upon activation by alloantigen and
is integral to their function in vivo. Many groups are currently
interested in expanding alloantigen-specific Treg ex vivo in order to
return these cells to patients receiving an allograft [58]. In order to
facilitate this, many studies have focused on identifying cell surface
markers that correlate with the regulatory function of T cells. Our
data suggests that it will also be important to consider the N-glycan
profile of Treg as this may influence the ability of Treg to home
correctly in vivo to sites where they mediate suppression, regardless
of their ability to suppress in an in vitro MLR.
Materials and Methods
Mice
CBA.Ca RAG-1 knockout (CBA RAG
2/2;H 2
k) mice were a
gift from Dr. D. Kioussis (Mill Hill, London, U.K.). BM3 TCR-
transgenic mice (BM3; H2
k) [59] and CBK mice (H2
k+K
b as a
transgene) were a gift from Prof. A.L. Mellor (Institute of
Molecular Medicine and Genetics, Augusta, GA). BM3 mice
were crossed to a CBA RAG
2/2 background for these studies,
therefore all of their CD8
+ T cells are specific for the MHC I K
b
molecule. CBA.Ca (CBA; H2
k) and C57BL/10 (B10; H2
b) mice
were originally purchased from Harlan Olac. All mice were bred
in the SPF facility, Biomedical Services, JR Hospital, Oxford. All
experimental mice were sex- and age-matched aged between 6
and 12 wk at the time of the first procedure. All mice were bred
and used in accordance with the Animals (Scientific Procedure)
Act 1986 of the UK.
Reagents and Monoclonal Antibodies
Non-depleting anti-CD4 (YTS 177.9) and anti-CD8 (YTS 169)
[60] hybridomas were kindly provided by Prof H. Waldmann (Sir
William Dunn School of Pathology, Oxford, UK). TIB120 (anti-
MHC II), M1/70 (anti- Mac-1), and R3-6B2 (anti- B220)
hybridomas were obtained from ATCC, Manassas, VA. All
antibodies were produced in vitro, purified by chromatography and
confirmed to be endotoxin free before use in vivo.
Pre-Treatment Protocol
CBA mice received anti-CD4 mAb YTS177.9 (177) plus B10
(donor-specific transfusion (DST)) blood intravenously as previ-
ously described [20]. Spleens, ALN and MLN were harvested
on d 0. Cells from these 177/DST pre-treated animals are termed
‘‘pre-treated’’.
Purification of T Cells by FACS Sorting, for Real-Time PCR
Analysis of Gene Expression
Spleens were harvested from mice and CD4
+ cells were purified
as previously described [61]. Cells were stained for cell surface
CD4 and CD25 and were selected using a FACS aria flow
cytometer (BD Biosciences). Cell purity was analyzed by flow
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1,2-mannosidase was quantified by real-time PCR as described
previously [11].
Purification of Treg and Responder CD4+ Cells
CD25
2CD4
+ responder T cells were isolated from LN and
spleens of naive CBA, and CD25
+CD4
+ Treg were obtained from
LN and spleens of either naı ¨ve or pre-treated mice. CD4
+ cells
were purified, as described previously [61]. CD25
+ and CD25
2
cells were purified using a CD25 microbead kit, following
manufacturer’s instructions (Miltenyi Biotec Ltd., Bisley, U.K.).
Purity was determined by flow cytometry. Cells were typically
.90% pure.
Measurement of Surface N-Glycosylation Levels
Cells were resuspended in PBS (Oxoid, UK) containing 1 mg/
ml biotinylated PHA-L (Vector Labs, Burlingame, CA). Cells were
then stained with anti-CD25-FITC, anti-CD4-APC (Insight
Biotechnology) and streptavidin-PE (BD Biosciences), acquired
by flow cytometry.
Inhibition of Alpha-1,2-Mannosidase
For pre-incubation with KIF (Toronto Research Chemicals,
Canada), cells were resuspended in PBS+2% FCS (P.A.A.
Laboratories GmBH) containing 40 mM KIF (Treg
KIF) or control
PBS only (Treg). Cells were incubated at room temperature for
30 min.
In Vitro Suppression Assay
CD25
2CD4
+ ‘‘responder’’ cells were purified from CBK mice.
Responder cells were labeled with 5 mM CFSE (Invitrogen) as
previously described [32]. Cells were cultured in U-shaped 96-well
plates (Corning Costar) at with various ratios of Treg from naı ¨ve
CBA. Culture medium was composed of RPMI 1640 (Invitrogen)
supplemented with 10% FCS (both P.A.A. Laboratories GmBH),
2 mM L-glutamine (Invitrogen), 0.5 mM 2-ME (Sigma-Aldrich),
and 100 U/ml each penicillin and streptomycin (Invitrogen).
Responder cells were stimulated with either CD3/CD28 T Cell
Expander beads (Invitrogen), or irradiated B10 splenocytes.
Potential binding of Fc receptors were blocked with Fc block
(BD Biosciences), and cells were stained with anti-CD4-APC
(Insight Biotechnology), anti-K
b-biotin (BD Biosciences) followed
by streptavidin-PE (BD Biosciences). Viability was determined
using 7-AAD (BD Biosciences). Samples were acquired by flow
cytometry. The total number of cells after 6 d was calculated by
adding a fixed number of 6 mM synthetic fluorescent beads
(CaliBRITE; BD Biosciences) to each sample.
In Vitro Adhesion Assay
Treg were incubated for 24 h with CD3/CD28 T Cell
Expander beads. 2610
4 cells / well were transferred to Maxisorp
plates pre-coated with either 2.5% BSA (Sigma), bovine
fibronectin (Sigma), 20 mg/ml rICAM1-Fc (R&D) or 20 mg/ml
rMADCAM-1/Fc (R&D). Cells were centrifuged at 100 g for
1 min. After 45 min wells were gently washed 56with PBS and
resuspended in PBS. CellTitre Glo (Promega, UK) was added to
the wells and samples were transferred to an opaque white 96-well
plate (BD Biosciences). Values were measured using a luminom-
eter (Lucy; Anthos Eugendorf Austria). Standard numbers of
CD25
+CD4
+ cells were measured in parallel to generate standard
curves in order to determine the percentage adherence.
Stamper-Woodruff Assay
A modified Stamper-Woodruff protocol [30] was performed.
ALN were collected from 5 CBA, pelleted together and snap-
frozen in liquid nitrogen. Frozen tissue samples were cut to a
thickness of 7 mm and allowed to air-dry on microscope slides for
2 h. A hydrophobic circle was drawn around each section, and the
sections were placed on an orbital shaker at 4uC at 80 rpm.
Treg were cultured for 24 h with CD3/CD28 beads + hrIL-2
and were labeled with 5 mM CFSE. 100 ml of Treg (10
5) were
added and rotated over the sections for 45 min. Unbound cells
were removed by washing in PBS. Treg bound to HEV were fixed
by placing sections in cold 1.5% glutaraldehyde overnight. To
block L-selectin binding, cells were pre-treated with Mel-14
antibody at 20 mg/ml for 30 min. Pretreated cells were rotated
over the sections as described above. The number of CFSE-
labeled cells bound to HEV was counted blind.
In Vivo Tracking Assay
BM3 CD8 cells were purified and labeled with CFSE as
previously described [33]. 10
5 BM3 cells were adoptively
transferred into CBA Rag1
2/2 mice along with 5610
5 Treg.
Unless stated, mice received a B10 skin graft 1 day later. At days 5,
10 or 15 post-transplant, a single-cell suspension was prepared
from spleen, MLN, and draining or contralateral ALN. For
analysis of BM3 tracking, cells were processed as previously
described [32]. For analysis of CD4 cells tracking, cells were
stained with anti-CD4-APC, anti-TCRb-PE and anti-CD25-bio.
All samples were then stained with Streptavidin-PECy5 (BD
Bioscience) and acquired by flow cytometry. A fixed number of
6 mM synthetic fluorescent beads (CaliBRITE beads; BD
Biosciences) were added to each sample in order to determine
cell numbers.
Adoptive Transfer and Skin Graft Survival Assay
T cell–deficient CBA Rag1
–/– mice were reconstituted i.v. with
syngeneic fractionated T cells. One day after reconstitution, mice
received a B10 skin graft as previously described [12]. Grafts were
monitored and rejection was defined by complete destruction of
the skin.
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